GlobeNewswire Inc. · Oct 12, 2023
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
Approved Merger with Notable Labs and All Other Proposals
VB
NASDAQ · VBLT
Vascular Biogenics Ltd.
Healthcare · Biotechnology
$0.16
Down-$0.02 (-8.77%)
Updated Aug 15, 2026, 1:06 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.11M
- P/E ratio
- -0.05
- Dividend yield
- 0.00%
- 52-week range
- $3.53 – $11.20
- Volume
- 161.51K
- Avg. volume
- 38.15K
Price performance
VBLT price history
1M range · 0 trading sessions · Daily adjusted prices
VBLT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest VBLT news
The latest Smart Investors Daily articles mentioning VBLT.
Stock researchCompany · Overview
VBLT research
Overview
Company profile and research snapshot.
Company profile
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $5.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2022 | Chardan Capital | Neutral | — |
| Jul 20, 2022 | HC Wainwright & Co. | Neutral | — |
| Apr 28, 2022 | Chardan Capital | Buy | — |
| Jun 3, 2021 | Roth Capital | Buy | — |
| Jan 28, 2021 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 14, 2023
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval
GlobeNewswire Inc. · May 15, 2023
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals
PennyStocks · Apr 19, 2023
Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy? 10 Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
